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Abstract NO-(carboxymethyl)lysine (CML) is known to be
formed by oxidative cleavage of Amadori products between C-2
and C-3 of the carbohydrate chain. We report here that CML
formation from Amadori compounds is highly accelerated under
alkaline conditions. Incubation of glycated human serum albumin
(HSA) in 0.1 N NaOH led to the formation of CML whereas
glycated HSA reduced by NaCNBH3 or non-glycated HSA did
not generate CML. NK-t-butyloxycarbonyl-NO-fructoselysine
(Boc-FL), a model compound of Amadori product, was converted
to CML under alkaline conditions. CML level of human sera
(n = 224) preincubated with 0.1 N NaOH correlated well with
glycated albumin value (r = 0.912) and hemoglobin A1c
(r = 0.797).
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1. Introduction
Long-term incubation of proteins with glucose leads,
through the formation of early products such as a Schi¡
base and Amadori product, to advanced glycation end prod-
ucts (AGEs) which are characterized by £uorescence, brown
color and cross-linking [1]. Immunological studies using a
monoclonal anti-AGE antibody, 6D12 [2], not only demon-
strated the presence of AGEs in vivo, but also suggested a
potential link of AGEs to aging [3^5] and age-enhanced dis-
eases such as diabetic complications [6,7], atherosclerosis [8^
10], dialysis-related amyloidosis [11,12] and actinic elastosis of
the photoaged skin [13]. Reddy et al. [14] identi¢ed NO-(car-
boxymethyl)lysine (CML) [15] as a major antigenic determi-
nant in AGE proteins and our previous work also revealed
that 6D12 recognized a CML protein adduct as an epitope
[16], strongly suggesting an importance of CML among AGE
structures in vivo. In addition to these immunological studies,
the accumulation of CML-modi¢ed proteins in vivo has been
demonstrated by chemical measurement [17^20].
CML is formed in three pathways in vitro, by oxidative
cleavage of Amadori products [15,21] or Schi¡ bases [22,23]
between C-2 and C-3 of the carbohydrate chain or by mod-
i¢cation with glyoxal generated directly through autoxidation
of glucose [24,25]. Above all, the ¢rst one is thought to rep-
resent a major pathway in vivo [26]. CML formation from
Amadori product was accelerated by the addition of Fe3
[27] and was inhibited by the presence of chelators, reducing
agents, or radical scavengers [28^30]. We recently demon-
strated that hydroxyl radical generated by the reaction of
Fe2 with H2O2 mediates CML formation from Amadori
compounds [30]. CML is therefore termed ‘glycoxidation
product’ among AGE structures and proposed as a potential
biomarker of oxidative damage of tissue proteins in vivo
[28,29].
Johnson et al. showed that 1-deoxy,1-morpholinofructose, a
synthetic Amadori rearrangement product, increases its ca-
pacity to reduce nitroblue tetrazolium (NBT) with an increase
in pH [31]. Furthermore, Sakurai et al. [32] later showed that
the superoxide anion production from glycated polylysine
(used as an Amadori product) in vitro occurs preferentially
in alkaline medium. Based on these data, it seems reasonable
to expect that CML formation from Amadori products is
enhanced under alkaline condition. This possibility was tested
in the present study.
2. Materials and methods
2.1. Subjects
Venous blood samples were obtained from 224 fasting healthy or
diabetic subjects. Serum was separated by centrifugation at 1500Ug at
room temperature and stored at 380‡C before determination. Anti-
coagulated whole blood was collected into EDTA-2Na-containing
tubes to determine stable hemoglobin A1c (HbA1c).
2.2. Preparation of non-glycated and glycated standard
Non-glycated human serum albumin (HSA) was prepared by ex-
cluding glycated fraction from HSA [33]. One g of HSA (fraction V,
Sigma, St. Louis, MO) was incubated with phenyl boronic acid resin
(PBA-60, Amicon, Beverly, MA) in 800 ml of 0.5 M glycine-NaOH
bu¡er containing 2% MgCl2 (pH 8.5) for 2 h at room temperature.
The ¢ltrate through a glass ¢lter was again incubated with another
portion of the same resin. The ¢nally obtained solution was concen-
trated to 30 mg/ml by an ultra¢ltration system, followed by dialysis
against phosphate-bu¡ered saline (PBS) and was used for the experi-
ments. The level of fructosamine in the non-glycated HSA (30 mg/ml)
determined by fructosamine assay kit (Boehringer Mannheim, Mann-
heim, Germany) was negligible (10.9 Wmol/l). To prepare glycated
standard, a portion of the non-glycated standard solution was further
concentrated to 80 mg/ml using an ultra¢ltration system. We added
830 mg of D-glucose to the non-glycated standard solution (2.5 ml)
followed by incubation with stirring at 56‡C for up to 80 min. Time
aliquots were taken and cooled on ice and dialyzed against PBS. The
prepared solution (protein concentration of 30 mg/ml) was used as
glycated standard in the present study. The fructosamine contents of
normal HSA and glycated HSA (30 mg/ml) were 284 Wmol/l and 1186
Wmol/l, respectively.
2.3. Preparation of AGE-BSA
Bovine serum albumin (BSA, 50 mg/ml, fraction V, Sigma) was
incubated with 2.0 M D-glucose in 10 ml of 0.5 M sodium phosphate
bu¡er (pH 7.4) at 37‡C for 1 month followed by dialysis against PBS.
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2.4. Incubation of glycated or non-glycated proteins in alkaline
condition
Glycated or non-glycated standard HSA (2 mg/ml) was incubated
in 0.1 N NaOH or PBS at 37‡C for 16 h, followed by dialysis against
PBS. In order to reduce Amadori products into hexitollysine, glycated
proteins were preincubated at 4‡C for 16 h in 1.0 ml of PBS contain-
ing 50 mM NaCNBH3, followed by dialysis against PBS. Upon acid
hydrolysis of glycated HSA and subsequent amino acid analysis iden-
tical to Fig. 2, we detected a peak corresponding to furosine with a
retention time of 35.21 min. However, when glycated HSA was pre-
treated with NaCNBH3, the peak of furosine disappeared but two
peaks of hexitollysine (glucitollysine and mannitollysine) appeared
between phenylalanine and lysine (data not shown), indicating that
the Amadori product is reduced by NaCNBH3. After the alkaline
treatment, CML formation was determined by enzyme-linked immu-
nosorbent assay (ELISA) and amino acid analysis. Human sera ob-
tained from healthy or diabetic subjects were diluted at 1:80 with 0.1
N NaOH and were incubated at 37‡C for 16 h.
2.5. Enzyme-linked immunosorbent assay (ELISA)
CML-HSA was prepared as described previously [14]. Brie£y, 175
mg of HSA was incubated at 37‡C for 24 h in 1.0 ml of 0.2 M sodium
phosphate bu¡er (pH 7.8) containing 0.15 M glyoxylic acid and 0.45
M NaCNBH3, followed by dialysis against PBS. A mouse monoclonal
anti-AGE antibody, 6D12, which recognized CML protein adduct
[2,16] was used to detect CML in the alkaline-treated samples. Assays
were performed at room temperature by non-competitive and com-
petitive ELISA [2,16]. In a non-competitive ELISA, each well of a 96-
well microtiter plate (Immunoplate II, Nunc, Roskilde, Denmark) was
coated with 100 Wl of the sample to be tested in 50 mM sodium
carbonate bu¡er (pH 9.6), blocked with 0.5% gelatin and washed
three times with PBS containing 0.05% Tween 20 (washing bu¡er).
Wells were incubated with 0.1 Wg/ml of 6D12 (100 Wl) dissolved in
washing bu¡er for 1 h and then with horseradish peroxidase (HRP)-
conjugated anti-mouse IgG antibody (Kirkegaard Perry Laboratories,
Gaithersburg, MD). When human sera were examined, biotin-labeled
6D12 and avidin-biotin-horseradish peroxidase complex (Vector Lab-
oratories, Burlingame, CA) were used to avoid cross-reaction between
human IgG and anti-mouse IgG antibody. In a competitive ELISA,
each well was coated with 100 Wl of 10 Wg/ml CML-HSA and was
blocked with 0.5% gelatin. After washing three times with washing
bu¡er, the wells were incubated with the sample to be tested (50 Wl)
and 0.1 Wg/ml of 6D12 (50 Wl) for 1 h. The wells were incubated with
HRP-conjugated anti-mouse IgG antibody, followed by the reaction
with 1,2-phenylenediamine dihydrochloride. The reaction was termi-
nated by 1.0 M sulfuric acid, and the absorbance at 492 nm was read
on a micro-ELISA plate reader. For experiments using ELISA, the
same set of experiment was repeated at least three times and the
representative data were shown in each ¢gure.
2.6. Amino acid analysis
CML contents of modi¢ed proteins were quantitated by amino acid
analysis as described previously [16,30]. After acid hydrolysis with 6 N
HCl for 24 h at 110‡C, samples were subjected to an amino acid
analyzer (Model 835, Hitachi, Tokyo) using an ion-exchange HPLC
column (#2622 SC, 4.6U60 mm, Hitachi Co.) and ninhydrine post-
column detecting system. Hippuryl-CML was prepared by incubating
hippuryllysine (benzoylglycyllysine, Peptide Institute, Osaka, Japan)
with glyoxylic acid and NaCNBH3 as described [16] and was used
as a standard CML. The identity of CML detected by HPLC was
con¢rmed by fast atom bombardment (FAB) mass spectrometry. The
model Amadori compound, NK-t-butyloxycarbonyl-NO-fructoselysine
(Boc-FL) was synthesized as described previously [34]. The purity was
assessed by a reverse phase HPLC (column: Shimadzu Techno Re-
search STR-ODSII; eluent: 30% methanol in 0.1% TFA) and the
structure was con¢rmed by 1H-NMR (Bruker ARX-500) and sput-
tered ion mass spectrometry (Hitachi M-80B).
2.7. Determination of glycated albumin and stable HbA1c
The amount of glycated albumin was determined with glycated
albumin assay kit (Labo¢t Glycoalbumin, Nacalai Tesque, Kyoto,
Japan) [33]. To each well of a 96-well microtiter plate coated with
anti-HSA antibody we added 50 Wl of 10 mM phosphate bu¡er (pH
7.4) containing 0.05% Tween 20 and then 20 Wl of the test sample.
After incubation for 20 min, the wells were washed three times with
5 mM sodium carbonate bu¡er containing 2% MgCl2 (washing bu¡er)
and incubated for 20 min with the boronate-horseradish peroxidase
conjugate in 50 Wl of 100 mM glycine-NaOH (pH 9.0) containing 2%
MgCl2, 0.3% bovine hemoglobin and 0.05% Tween 20. The wells were
then washed ¢ve times with the washing bu¡er and reacted for 20 min
in the dark with 1 mg/ml o-phenylenediamine in 50 Wl of 0.1 M citrate
bu¡er (pH 5.8) containing 0.015% H2O2. The reaction was terminated
by adding 50 Wl of 2 N sulfuric acid. Absorbance (A) was measured at
492 nm by a microplate reader (MTP-120, Corona Electronic, Japan).
Non-glycated standard albumin (NGA) and glycated standard albu-
min with a glycated albumin level of 40% (GA 40%) were used as
standards to determine the level of glycated albumin in each sample.
The percentage of glycated albumin in each sample (% GA) was
calculated according to the formula:
% GA  A of sample3A of NGA
A of GA 40%3A of NGA
U40%:
Stable HbA1c of the anticoagulated whole blood was determined
by an automated stable glycated hemoglobin analyzer (HLC-
723GHbIII-S, Tosoh, Tokyo, Japan). The system is based on the
high-performance ion-exchange liquid chromatographic method.
3. Results
3.1. E¡ect of alkaline treatment on the immunoreactivity
of AGE-BSA
Using AGE-BSA, obtained by the incubation with glucose
for 1 month, the e¡ect of alkaline treatment on the immuno-
reactivity toward 6D12 was examined. After incubation in 0.1
N NaOH at 4‡C for 16 h, the immunoreactivity of AGE-BSA
was markedly increased compared with the incubation in PBS
(Fig. 1A). Alkaline-treated BSA slightly but signi¢cantly re-
acted with 6D12, whereas PBS-treated BSA showed no immu-
noreaction. Because these samples did not react with non-im-
mune mouse IgG used as a negative control for 6D12 (data
not shown), the immunoreactivity with 6D12 was considered
speci¢c for CML. In a competitive ELISA (Fig. 1B), the im-
munoreactivity in alkaline-treated AGE-BSA was V100-fold
higher than PBS-treated one. BSA showed signi¢cant immu-
noreaction only after the alkaline treatment. It was possible
that CML moiety was exposed by the protein-degenerative
e¡ect of alkaline solution as suggested previously [35,36].
However, it might be due to additional formation of CML
by alkaline treatment.
3.2. CML formation under alkaline condition determined
by amino acid analysis
To test this, CML content of AGE-BSA was measured by
amino acid analysis. CML content of alkaline-treated AGE-
BSA (1.220 mol/mol of BSA) was signi¢cantly higher than
PBS-treated one (0.085 mol/mol of BSA). It is likely, there-
fore, that additional formation of CML did occur under al-
kaline condition and CML might be formed by oxidative
cleavage of protein-bound Amadori adducts [15,21]. To fur-
ther con¢rm the formation of CML from Amadori com-
pounds, the model Amadori compounds such as Boc-FL
and glycated HSA were incubated under alkaline condition.
When 1 nmol of Boc-FL was subjected to acid hydrolysis and
amino acid analysis, 0.811 nmol of lysine residue was recov-
ered as one of decomposition products, whereas CML was not
detectable (6 0.005 nmol) (Fig. 2A). However, after incuba-
tion in 200 Wl of 0.1 N NaOH at 37‡C for 16 h, 0.274 nmol of
CML was formed (Fig. 2B). Since CML was not detectable in
alkaline-treated glycated standard HSA, we prepared highly
glycated HSA (high contents of Amadori products and low
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level of CML) as described [29,30,37]. HSA (50 mg/ml) was
incubated for 7 days at 37‡C with 1.6 M glucose in 10 ml of
50 mM sodium phosphate bu¡er (pH 7.2) in the presence of
1 mM diethylenetriaminepentaacetic acid (DTPA). The fruc-
tosamine level of the highly glycated HSA (30 mg/ml) was
3189 Wmol/l. CML content of this highly glycated HSA
(2 mg/ml) was undetectable (Fig. 2C), whereas CML became
a detectable level of 1.11 mol/mol of HSA after incubation in
the same alkaline condition (Fig. 2D). CML was not gener-
ated by the alkaline treatment of non-glycated standard HSA
for 16 h, nor by parallel incubation of highly glycated HSA
with PBS (data not shown). These data indicated that CML
formation from Amadori product in alkaline condition was
faster than that in neutral conditions.
3.3. CML formation from Amadori products in glycated
standard HSA and human sera under alkaline condition
This notion was further tested by determining the e¡ect of
alkaline condition on the CML formation from glycated HSA
or human sera. As shown in Fig. 3A, alkaline treatment in-
creased the immunoreactivity of glycated standards according
to the glycated albumin levels, although PBS treatment had
no e¡ect on it. CML formation by the alkaline treatment was
not observed in non-glycated standards (Fig. 3A), nor in glyc-
ated standard which had been preincubated with NaCNBH3
in advance (data not shown). Similarly, alkaline treatment
increased the immunoreactivity of human sera according to
the glycated albumin levels (Fig. 3B). These data demon-
strated that CML was arti¢cially formed from protein-bound
Amadori adducts under the alkaline condition. CML content
of these alkaline-treated glycated standards or human sera
was less than a detectable level of amino acid analysis
(6 0.01 mol/mol of HSA).
3.4. The immunoreactivity of alkaline-treated human sera
was speci¢c for CML
To examine whether the immunoreactivity re£ected the true
amount of CML formed, the speci¢city was examined by
competitive ELISA using CML-BSA or CML-modi¢ed pep-
tide, hippuryl-CML, as standards. As shown in Fig. 4A, the
immunoreaction of alkaline-treated human sera (B0) was com-
pletely inhibited by CML-BSA and hippuryl-CML but not by
their unmodi¢ed counterparts, BSA and hippuryllysine. On
the other hand, the immunoreactivity of CML-BSA was sig-
ni¢cantly inhibited by the alkaline-treated human sera accord-
ing to their glycated albumin levels (Fig. 4B). From these
speci¢c immunoreaction to CML, it is evident that the immu-
noreaction re£ects the amount of CML formation in a speci¢c
manner.
3.5. Correlation between the immunoreactivity of the
alkaline-treated human sera with 6D12 and glycated
albumin level or stable HbA1c
Therefore, CML level of alkaline-treated human sera was
determined by non-competitive ELISA using 6D12. It corre-
lated well with the levels of glycated albumin (Fig. 5A). The
regression line was y = 0.0141x+0.0849 (n = 224, r = 0.912).
This correlation again suggested that the immunoreactivity
re£ected CML formed from Amadori adducts of serum pro-
teins under alkaline condition. CML formation was also cor-
related with HbA1c (Fig. 5B, r = 0.797).
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Fig. 1. Immunoreactivities of AGE-BSA and BSA incubated under alkaline or physiological condition were determined by non-competitive (A)
and competitive (B) ELISA using 6D12. AGE-BSA (1.0 mg/ml) incubated in 1.0 ml of 0.1 N NaOH (F) or PBS (E) at 4‡C for 16 h was sub-
jected to ELISA. BSA was incubated in either 0.1 N NaOH (b) or PBS (a) in the same way.
Fig. 2. CML formation under alkaline condition was determined by
amino acid analysis. Boc-FL (1 nmol) was incubated in PBS (A) or
0.1 N NaOH (B) at 37‡C for 16 h, followed by acid hydrolysis and
amino acid analysis. Highly glycated HSA (2.0 mg/ml) was incu-
bated in PBS (C) or 0.1 N NaOH (D) at 37‡C for 16 h, followed
by dialysis against PBS and was subjected to amino acid analysis.
NH3 represents a peak of ammonia.
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4. Discussion
We show here that under alkaline condition, CML is
formed from Amadori compounds of in vitro glycated HSA
and those of healthy or diabetic sera. Incubation of glycated
HSA in 0.1 N NaOH led to the formation of CML whereas
glycated HSA reduced by NaCNBH3 or non-glycated HSA
did not generate CML. CML level of human sera (n = 224)
incubated with 0.1 N NaOH for 16 h at 37‡C correlated
well with glycated albumin value. Likewise, alkaline-treated
BSA also signi¢cantly increased its reactivity to 6D12 (Fig.
1A and B). These data indicated that Amadori compounds of
HSA or BSA were converted to CML under alkaline condi-
tion.
Tissue proteins showed strong immunoreactivity to anti-
AGE antibodies after the treatment in alkaline condition
[35,36]. In these studies, the immunoreactivity was obtained
after the samples were incubated in 0.1 N NaOH solution for
12 h at 4‡C and it was supposed that alkaline treatment might
degenerate proteins so that AGEs exposed to the surface of
the protein could easily be recognized by the antibody. How-
ever, as shown in the present study, it was possible that CML
was arti¢cially formed from Amadori products under alkaline
condition.
The immunoreactivity of an alkaline-treated serum with
6D12 might re£ect its amount of Amadori compounds, since
it correlated very well with markers for glycemic control such
as glycated albumin and HbA1c (Fig. 5). It was, therefore,
likely that the contents of Amadori compound in human sera
could be quantitated by ELISA using 6D12. It was also noted
that the correlation coe⁄cient was higher in glycated albumin
than in HbA1c probably because the glycated albumin level
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Fig. 4. Speci¢city of the immunoreaction of alkaline-treated human sera toward 6D12 was examined by competitive ELISA. A: Wells were
coated with alkaline-treated diabetic serum with a glycated albumin level of 25.0% and were reacted with 6D12 in the presence or absence of
competitors. Used competitors were: hippuryllysine (E), hippuryl-CML (F), BSA (O), and CML-BSA (R). B: Wells were coated with 0.2 Wg/
ml CML-BSA and were reacted with 6D12 in the presence of alkaline-treated human sera. Human sera with the designated glycated albumin
level of 5.4, 12.7, 25.0, 35.5 and 43.2% were used as competitors. The results were expressed as the ratio B/B0 in which B represents the
amount of binding of 6D12 in the presence of a competitor and B0 represents that in the absence of it.
Fig. 3. CML formation in glycated standard HSA (A) or human sera (B) under alkaline condition was determined by non-competitive ELISA
using 6D12. A: Glycated standard HSA with a glycated albumin level of 40% was mixed with non-glycated standard HSA to obtain the stand-
ards with glycated albumin level of 0, 10, 20 and 30%. These standards (1.0 mg/ml) were incubated in 1.0 ml of 0.1 N NaOH (b) or PBS (a)
at 37‡C for 16 h, followed by dialysis against PBS. B: Human sera obtained from healthy or diabetic subjects were diluted at 1:80 with 0.1 N
NaOH (b) or PBS (a) and were incubated at 37‡C for 16 h. CML formation in each sample at a ¢xed concentration (10 Wg/ml) was deter-
mined by non-competitive ELISA. CML levels were expressed as the absorbance at 492 nm.
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more directly re£ected the amount of Amadori adducts which
could be the source of CML in human sera.
Amadori products, also known as fructosamines, are
formed by the Amadori rearrangement of Schi¡ base adducts
of glucose with protein amino groups. Fructosamines are re-
ductants under alkaline condition [31], a property used in the
colorimetric assay of serum protein glycation, in which such
proteins reduce the dye nitroblue tetrazolium [31]. Recent
studies have demonstrated the generation of reactive oxygen
species including O32 and H2O2 from Amadori products
[21,32,38^40]. Furthermore, reactive oxygen species derived
from Amadori compounds have been shown to be responsible
for damage to amino acids, proteins, lipids, and DNA, which
was catalyzed by transition metal ions [41^45]. Although the
extreme alkaline conditions such as 0.1 N NaOH cannot be
achieved in vivo even in some disease states, CML formation
could be accelerated locally when glycated proteins are sub-
jected to long-term exposure to mild alkaline conditions.
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